SAGILITYNSE30 July 2025

Sagility India Limited has informed the Exchange about Investor Presentation

SAGILITY LIMITED

Date: July 30, 2025

To, The Manager Listing Department National Stock Exchange (NSE) Exchange Plaza, 5th Floor Plot No. C/1, G-Block Bandra-Kurla Complex Bandra (E), Mumbai - 400 051 Symbol: SAGILITY

Dear Sir/Ma’am,

To, The Manager Listing Department Bombay Stock Exchange (BSE) Phiroze Jeejeebhoy Towers Dalal Street Mumbai - 400 001 Scrip Code:544282

Subject: Submission of Investor Presentation to be made to investors on July 30, 2025, pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

In continuation to our letter dated July 16, 2025, we are enclosing herewith the presentation to be made to Investors on the Financial Results of Sagility India Limited for the quarter ended June 30, 2025, scheduled today i.e., on Wednesday, July 30, 2025 at 7:30PM (IST).

The details are also being made available on the Company’s website https://sagilityhealth.com/

This is for your kind information and record.

Thanking You,

For Sagility India Limited

Satishkumar Sakharayapattana Seetharamaiah    Company Secretary & Compliance Officer    M. No: A16008

Encl: a/a

Sagility India Limited (Formerly Sagility India Private Limited) Registered Office - No. 23 & 24, AMR Tech Park, Building 2A, First Floor Hongasandara Village, Off Hosur Road, Bommanahalli, Bengaluru – 560068 Karnataka India Corporate Identification Number: L72900KA2021PLC150054 Tel. No.: 080-71251500, Website: www.sagilityhealth.com

July 30, 2025

Investor Deck – Q1 FY26

Safe Harbour

Certain statements in this release concerning Sagility’ future growth prospects may be seen as forward- looking statements, which involve a number of risks and uncertainties that could cause the actuals to differ materially from such statements. Sagility does not undertake to update any such statement that may have been made from time to time by or on behalf of the company..

Q1 FY26 Performance Highlights

₹ 15,389 million

₹ 3,687 million

₹ 1,997 million

Headcount 39,917

► 17.9% Y-o-Y organic growth in Q1 FY26 driven by expansion from existing

clients, while new wins are expected to further strengthen momentum in FY26

Y-o-Y growth 25.8% 23.1 % at Constant Currency

Organic Y-o-Y growth 17.9% 15.4 % at Constant Currency

Margin % 24.0%

Margin % 13.0%

Clinicians & Technology heads 3200+

► $32 M (potential steady state ACV) of new business & expansion won in Q1

FY26

► Expansion and new SOWs from 18 existing clients in Q1 FY26

Y-o-Y growth % 26.5%

Y-o-Y growth % 38.0%

Attrition* 27.6%

► 4 new clients onboarded in Q1

► Helping set-up a GCC for a client on a BOT model

► Operations remain robust, driven by strong performance across key metrics

► Sagility has been named a Leader by Avasant in both - the Healthcare Payer Business Process Transformation 2025 RadarView and in the

Clinical and Care Management Business Process Transformation 2025 RadarView

► Sagility won the ‘Most Preferred Workplace FY’26’ award by Marksmen Daily

Note: Adjusted EBITDA represents EBITDA adjusted for earnouts payable under the acquisition agreements (DCI, BirchAI & BroadPath), share-based payment awards and exclude other income (including forex gain/loss). *Voluntary attrition (considering employees who were employees for more than 90 days) on an annualized basis

Quarterly KPIs

Revenue from Operation (in INR Million)

15,389

15,685

12,233

25.8%

Q1 FY26

Q4 FY25

Q1 FY25

YoY%

Revenue by Vertical Split

By Payer %

By Provider %

88.4%

11.6%

89.7%

10.3%

89.1%

10.9%

Growth in revenue from operation (%)

25.8%

22.2%

9.6%

Adjusted EBITDA (in INR Million)

Adjusted EBITDA %

Adjusted PAT (in INR Million)

Adjusted PAT %

3,687

24.0%

1,997

13.0%

4,176

26.6%

2,398

15.3%

2,916

23.8%

1,447

11.8%

26.5%

38.0%

Total Number of Employees

39,917

39,409

35,858

11.3%

Voluntary attrition rate* (%)

27.6%

32.5%

27.3%

Note: Adjusted EBITDA represents EBITDA adjusted for earnouts payable under acquisition agreements (DCI, BirchAI & BroadPath), share-based payment awards and exclude other income (including forex gain/loss). Voluntary attrition (considering employees who were employees for more than 90 days) on an annualized basis

Annual KPIs

Number of Client groups*

Active

Number of new client addition (Gross)

Delivery sites

Number of delivery sites

New site addition (Gross)

Client groups contribution to revenues

Top 3 Client %

Top 5 Client %

Top 10 Client %

Number of Million-dollar client groups

Number of clients contributing more than US$20 million

Number of clients contributing to US$5 - US$20 million

Number of clients contributing to US$1 - US$5 million

Number of clients contributing less than US$1 million

* Client groups comprise client entities together with their affiliates.

Q1 FY26

FY25

FY24

FY23

TTM Jun 25

FY25

FY24

FY23

64.7%

76.3%

89.4%

66.2%

77.9%

90.5%

68.3%

79.2%

91.4%

72.4%

80.6%

90.7%

Market Updates

Market Changes

Impact on Payer/ Provider

Likely Impact on Sagility

One Big Beautiful Bill – Cuts in Federal Medicaid Spending

► Revenue and margin are expected to be impacted for both Payers (due to drop in Medicaid Memberships and Medicaid funding cuts) and Providers (due to rising uninsured populations and lower reimbursement rates).

► Low exposure to Medicaid ( mid-single digits).

Minimal impact of drop in Membership

► Increase in outsourcing by Payers & Providers to

manage costs.

Rising Medicare utilization rates impacting profitability

► This is expected to strain Payer margins;

► Increase in outsourcing to manage costs better;

however, CMS increased MA payments by 5.06% for CY2026

however, pricing pressure to increase

► Strong tailwinds for higher outsourcing in clinical

segment

Tariffs

► Likely tariff driven increase in cost of

► No tangible impact

imported medical equipment & Pharmaceuticals. Providers more exposed to Tariff risks than payers.

Growing adoption of generative and agentic AI

► GenAI is gaining ground though Adoption is

► Deep healthcare expertise and the continued

gradual. Emerging use cases. Domain expertise is the differentiator to driving meaningful outcomes

investments in building AI use cases in Healthcare, positions Sagility to deliver better business outcomes through lower cost and better end customer experience

Accelerating Value Delivery with AI

Client Use cases: As on date, we have deployed roughly 18 AI based use-cases across 8 clients. We are also working on 15+ additional use cases that are relevant to the work that we currently do for our clients. Some examples below:

Nurse Assist: Clinical reviews by enabling automated understanding and application of medical necessity guidelines across unstructured medical records

Appeals assist: AI driven real-time support system that classifies appeals, extracts information, helps in decision making and that helps improve star ratings for payors and for providers, analyses denial reasons, checks medical records, determines medical necessities and generate appeal letters

Engagement Audit and analytics: Using AI in engagement automation, audit and business intelligence solution for multi- channel interactions

Contract Validation: AI based extraction and normalization of terms from complex payer- provider contracts

In addition, we are building Agentic AI solutions to transform the way we run our business; Agentic AI collaborators will enhance our recruitment and training outcomes, lowering costs and helping us to serve our clients better

Financial Highlights

Q1 FY26 Financial Highlights

Strong Q1 FY26 Performance

₹ 15,389 million

₹ 3,687 million

₹ 1,997 million

₹ 3,211 million

Y-o-Y growth % 25.8% 23.1 % at Constant Currency

Organic Y-o-Y growth % 17.9% 15.4 % at Constant Currency

Margin % 24.0%

Margin % 13.0%

Y-o-Y growth % 26.5%

Y-o-Y growth % 38.0%

Conversion % 90.2%

DSO 75 days

Quarter wise performance

18,000

Headcount (‘000)

16,000

14,000

12,000

8,000

10,000 4 2 e n u J

6,000

4,000

2,000

33.5

11,161

12.8%

Q1 FY24

Headcount (‘000)

18,000

35.8

16,000

14,000

12,000

12,233

5 10,000 2 e n u J

8,000

6,000

o t 3 2 l i r p A

o t 4 2 l i r p A

36.5

10,941

11.5%

Q2 FY24

38.3

13,250

4,000

2,000

11.8%

12.3%

36.6

12,602

35.0

12,832

12.4%

12.9%

Q3 FY24

Q4 FY24

Revenue INR M

Adjusted PAT %

39.4

15,685

39.6

14,531

18.1%

Q1 FY25

Q2 FY25

Q3 FY25

Q4 FY25

Q1 FY26

Revenue INR M

Adjusted PAT %

* Q1 FY26 and Q4 FY25 Headcount includes BroadPath Headcount of 1,093 and 1,083 respectively (acquired in Q4 FY25)

15.3%

13.0%

35.8

12,233

11.8%

Q1 FY25

39.9

15,389

50.0%

45.0%

40.0%

35.0%

30.0%

25.0%

20.0%

15.0%

10.0%

5.0%

0.0%

50.0%

45.0%

40.0%

35.0%

30.0%

25.0%

20.0%

15.0%

10.0%

5.0%

0.0%

Impact of seasonality on Q1 vs Q4

Increase in ETR in Q1 vs Q4

Financial performance snapshot – Q1 FY26

Revenue (INR Million)

Y-o-Y

25.8%

Q-o-Q

-1.9%

Adjusted EBITDA* (INR Million)

₹15,685

₹15,389

₹12,233

₹2,916

Y-o-Y

26.5%

₹4,176

Q-o-Q

-11.7%

₹3,687

Adjusted PAT (INR Million)

₹1,447

Y-o-Y

38.0%

₹2,398

Q-o-Q

-16.7%

₹1,997

Q1'25

Q4'25

Q1'26

Q1'25

Q4'25

Q1'26

Q1'25

Q4'25

Q1'26

Revenue ($M)

$146.6

Y-o-Y

23.1%

Q-o-Q

-0.8%

$181.8

$180.4

Adjusted EBITDA* ($M)

$34.9

Y-o-Y

23.7%

$48.4

Q-o-Q

-10.7%

$43.2

Adjusted PAT ($M)

$17.3

Y-o-Y

35.2%

$27.8

Q-o-Q

-15.8%

$23.4

Q1'25

Q4'25

Q1'26

Q1'25

Q4'25

Q1'26

Q1'25

Q4'25

Q1'26

*Adjusted EBITDA represents EBITDA adjusted for earnouts payable under the acquisition agreements (DCI, BirchAI & BroadPath), share-based payment awards and exclude other income (including forex gain/loss).

Financial performance snapshot – Long Term

Revenue (INR Million)

FY25 YoY% TTM Jun YoY%

17.2%

21.1%

₹58,855

₹55,699

₹47,536

₹48,608

Adjusted EBITDA * (INR Million)

FY25 YoY% TTM Jun YoY%

28.4%

35.2%

Adjusted PAT (INR Million)

FY25 YoY% TTM Jun YoY%

37.5%

46.3%

₹14,685

₹15,456

₹8,107

₹8,657

₹11,436

₹11,432

₹5,896

₹5,919

FY24

FY25

TTM Jun'24

TTM Jun'25

FY24

FY25

TTM Jun'24

TTM Jun'25

FY24

FY25

TTM Jun'24

TTM Jun'25

Revenue ($M)

FY25 YoY% TTM Jun YoY%

14.9%

18.6%

Adjusted EBITDA* ($M)

FY25 YoY% TTM Jun YoY%

25.9%

32.5%

Adjusted PAT ($M)

FY25 YoY% TTM Jun YoY%

34.8%

43.4%

$572.9

$658.3

$583.8

$692.1

$173.6

$181.8

$137.8

$137.3

$95.8

$101.9

$71.1

FY24

FY25

TTM Jun'24

TTM Jun'25

FY24

FY25

TTM Jun'24

TTM Jun'25

FY24

FY25

TTM Jun'24

TTM Jun'25

Financial Indicators

Adjusted EPS (in INR)

1.76

1.85

1.38

47%

Adjusted ROCE %

55%

52%

FY'24

FY'25

TTM Jun'25

FY'24

FY'25

TTM Jun'25

Cash Conversion (%)

87.2%

70.8%

89.7%

80.5%

90.2%

81.0%

Net Debt

₹21,678

1.9x

₹10,432

0.71x

₹7,894

0.51x

2.00

1.50

1.00

0.50

₹25,000

₹20,000

₹15,000

₹10,000

₹5,000

₹0

FY'24

FY'25

YTD Jun'25

FY'24

FY'25

TTM Jun'25

OCF %

FCF %

Net Debt (in INR Million)

Net Debt to Adjusted EBITDA

Adjusted EPS is Adjusted PAT divided by weighted average number of equity shares Adjusted ROCE is Adjusted PAT plus Interest cost divided by capital employed (Assets excluding goodwill and intangibles assets less current liabilities) Net Debt is Borrowing plus lease liabilities less Cash and Cash equivalent. Borrowing doesn’t include accrued interest

Q1 FY26 Consolidated Profit and Loss Amt in INR M Particulars

Q4 FY25

Q1 FY26

Q1 FY25

Revenue from Operation

Employee benefits expense*

Other expenses^

Adjusted EBITDA**

Adjusted EBITDA %

Adjustments:

M&A Earnouts

SAR (stock appreciation right) – Non Cash

Other Income^^

Forex Gain / (Loss)

Reported EBITDA

Finance costs

Depreciation and amortisation

Profit Before Tax

Tax Expenses

Reported Profit After Tax

EPS

Adjusted PAT

Adjusted PAT %

Adjusted EPS (Rs)

15,389

15,685

12,233

9,646

2,056

3,687

24.0%

155

3,560

274

1,182

2,104

618

1,486

0.32

1,997

13.0%

0.43

9,429

2,079

4,176

26.6%

207

104

101

-135

3,832

298

1,143

2,390

564

1,826

0.39

2,398

15.3%

0.51

7,527

1,790

2,916

23.8%

124

852

209

2,184

374

1,100

710

487

223

0.05

1,447

11.8%

0.33

► Q1 26 Organic Revenue at INR

14,429 Mn (YoY% 17.9% and 15.4% at constant currency YoY%)

YoY%

25.8%

QoQ%

-1.9%

26.5%

-11.7%

63.0%

-7.1%

196.3%

-12.0%

566.4%

530.0%

38.0%

-18.6%

-16.7%

30.5%

-16.7%

*Employee benefits expense excludes M&A earnout and SAR (shown separately under adjustments), ^ Other expenses exclude forex loss. ^^ Other income excludes forex gain. Forex Gain and Forex Loss clubbed together and shown separately. ** Adjusted EBITDA represents EBITDA adjusted for earnouts payable under the acquisition agreements (DCI, BirchAI & BroadPath), share-based payment awards and exclude other income (including forex gain/loss).

Adjustments on EBITDA and PAT

Adj EBITDA Bridge: Q1 FY26

INR Million

₹3,560

₹155

₹71

-₹99

₹3,687

Reported EBITDA

Adj A

Adj B

Other Income/Fx gain

Adjusted EBITDA

Adj PAT Bridge: Q1 FY26

INR Million

₹1,486

₹113

₹71

₹327

₹1,997

Reported PAT

Adj A

Adj B

Adj C

Adjusted PAT

Adj A - Earnouts under acquisition agreements and for PAT it is adjusted for tax Adj B - Share based payment awards (non-cash expenses for the company and not tax deductible) Adj C - Amortization of intangible assets that got created due to carveout of healthcare business from HGS

Go Forward Positions

Amt in INR M

Particulars

Closing Debt position

Debt Repayment

Interest Payment

Share based Payment awards

Earnouts Cost - DCI / Birch/ BroadPath

Intangibles Amortisation (A)

Intangibles Amortisation (B)

FY25

FY26

FY27

FY28

FY29

FY30

8,020

2,490

751

1,134

571

1,400

188

5,670

2,350

535

251

495

1,419

381

5,670

285

147

1,419

371

1,419

356

1,419

284

1,419

240

• •

Intangibles Amortisation (A) - Amortization of intangible assets that got created due to carveout of healthcare business from HGS Intangibles Amortisation (B) - Amortisation for intangible assets acquired in relation to acquisitions (DCI, Birch and BroadPath) – Ends by FY33

Balance Sheet as on 30th June 25

Amt in INR M

Particulars

Property, plant and equipment

Capital-work-in-progress

Right-of-use assets

Goodwill

Other intangible assets

Trade receivables and Unbilled

Cash and cash equivalents

Deferred tax assets (net)

Other Assets

Total Assets

Equity

Borrowings

Lease liabilities

Trade payables

Deferred tax liabilities (net)

Other Liabilities

Total Liabilities

Jun 25

Mar 25

3,600

5,273

60,382

19,930

12,994

4,538

1,285

3,204

111,225

85,162

6,903

5,656

2,023

4,027

7,455

3,699

5,521

60,390

20,362

12,668

3,438

1,337

3,091

110,507

83,361

8,170

5,850

2,136

4,279

6,712

111,225

110,507

Cash Flow – Q1 FY26

Amt in INR M Particulars

Profit before tax for the period/ year

Adjustment for Non-Operating and Non-Cash items

Adjustment for working capital

Income taxes paid (net of refunds)

Net cash flows generated from operating activities (A) - OCF

Addition to Fixed Assets

Free Cash flow (FCF)

Cash paid for M&A

Pending Purchase consideration paid for healthcare business carveout

Others

Net cash flows (used in) investing activities (B)

Capital infused by promoter

Share Issue expense (paid)/ reimbursed

Repayment of Promoter borrowings (include Interest)

Repayment of lease liabilities (include Interest)

Net cash flows (used in) financing activities (C)

Net increase/ (decrease) in cash and cash equivalents (A+B+C)

Cash and cash equivalents at the beginning of the year/period

Effect of movement in exchange rates on cash and cash equivalents

Cash and cash equivalents at the end of the year/ period

Net cash flows generated from operating activities % (OCF on Reported EBITDA)

Free Cash flow % (FCF on Reported EBITDA)

Q1 FY26

FY25

2,104

1,552

(254)

(191)

3,211

(326)

2,885

(245)

(1,425)

(456)

(1,881)

1,086

3,438

4,538

90.2%

81.0%

7,602

6,982

(710)

(1,734)

12,141

(1,244)

10,896

(4,825)

(3,756)

184

(9,642)

3,708

(4,567)

(1,774)

(2,561)

(62)

3,441

3,438

89.7%

80.5%

P&L for Previous Quarters Amt in INR M Particulars

Q1 FY24

Revenue from Operation

Employee benefits expense*

Other expenses^

Adjusted EBITDA**

Adjusted EBITDA %

Adjustments:

M&A Earnouts

SAR (stock appreciation right) – Non Cash

Other Income^^

Forex Gain / (Loss)

Reported EBITDA

Finance costs

Depreciation and amortisation

Profit Before Tax

Tax Expenses

Reported Profit After Tax

EPS

Adjusted PAT

Adjusted PAT %

Adjusted EPS (Rs)

11,161

6,361

1,881

2,919

26.2%

282

100

2,751

471

1,661

619

194

425

0.10

1,424

12.8%

0.33

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

Q3 FY25

Q4 FY25

Q1 FY26

10,941

12,602

12,832

12,233

13,250

14,531

15,685

15,389

6,674

1,795

2,472

22.6%

132

193

2,632

483

1,715

434

350

0.08

1,254

11.5%

0.29

7,912

1,789

2,901

23.0%

-8

-164

2,659

468

1,756

435

-271

706

0.16

1,567

12.4%

0.37

7,925

1,764

3,143

24.5%

3,119

429

1,760

929

127

802

0.19

1,651

12.9%

0.39

7,527

1,790

2,916

23.8%

124

852

209

2,184

374

1,100

710

487

223

0.05

1,447

11.8%

0.33

7,912

1,874

3,465

26.1%

120

153

-241

3,165

297

1,264

1,604

431

1,173

0.25

1,636

12.3%

0.35

8,415

1,988

4,127

28.4%

120

341

4,362

302

1,162

2,898

729

2,169

0.46

2,626

18.1%

0.56

9,429

2,079

4,176

26.6%

207

104

101

-135

3,832

298

1,143

2,390

564

1,826

0.39

2,398

15.3%

0.51

9,646

2,056

3,687

24.0%

155

3,560

274

1,182

2,104

618

1,486

0.32

1,997

13.0%

0.43

*Employee benefits expense excludes M&A earnout and SAR (shown separately under adjustments), ^ Other expenses exclude forex loss. ^^ Other income excludes forex gain. Forex Gain and Forex Loss clubbed together and shown separately. ** Adjusted EBITDA represents EBITDA adjusted for earnouts payable for acquisitions (DCI, BirchAI & BroadPath), share-based payment awards and exclude other income / forex gain or loss).

Thank You

← All Transcripts SAGILITY Stock Page →

Sagility India Limited has informed the Exchange about Investor Presentation

Market Movers